Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up

被引：72

作者：

Scorsetti, Marta ^{[1
,2
]}

Comito, Tiziana ^{[1
]}

Clerici, Elena ^{[1
]}

Franzese, Ciro ^{[1
]}

Tozzi, Angelo ^{[1
]}

Iftode, Cristina ^{[1
]}

Di Brina, Lucia ^{[1
]}

Navarria, Pierina ^{[1
]}

Mancosu, Pietro ^{[1
]}

Reggiori, Giacomo ^{[1
]}

Fogliata, Antonella ^{[1
]}

Tomatis, Stefano ^{[1
]}

Torzilli, Guido ^{[2
,3
]}

Cozzi, Luca ^{[1
,2
,4
]}

机构：

[1] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Radiotherapy & Radiosurgery Dept, Via Manzoni 56, I-20089 Milan, Italy

[2] Humanitas Univ, Dept Biomed Sci, Via Manzoni 113, I-20089 Milan, Italy

[3] Humanitas Clin & Res Ctr, Dept Hepatobiliary Surg, Via Manzoni 56, I-20089 Milan, Italy

[4] Humanitas Res Hosp & Canc Ctr, Radiotherapy & Radiosurg Dept, Via Manzoni 56, I-20089 Milan, Rozzano, Italy

来源：

RADIATION ONCOLOGY | 2018年 / 13卷

关键词：

Metastatic liver cancer; SBRT; SABR; Volumetric modulated arc therapy; STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; HEPATIC RESECTION; COLORECTAL METASTASES; DOSE-ESCALATION; CANCER; TUMORS; CHEMOTHERAPY; HISTOLOGY; SURGERY;

D O I：

10.1186/s13014-018-1185-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The aim of this study was to evaluate long-term efficacy and survival prognostic factors of stereotactic body radiation therapy (SBRT) for un-resectable liver metastases in patients enrolled in a prospective phase II trial. Methods and materials: 5-year local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates were analyzed in patients with un-resectable liver metastases enrolled in a Phase II Trial on liver SBRT, with a prescription dose of 75Gy in 3 consecutive fractions. Results: A total of 61 patients with 76 lesions were enrolled, with a median follow-up time of 6.1 years. One, three and 5 year LC rates were 943.1%, 78.0 +/- 5.9% and 78.0 +/- 5.9%, without reaching the median LC time. Median OS was 27.6months and the survival rates were 85.2 +/- 4.5%, 31.1 +/- 5.9% and 18.0 +/- 4.9% at 1, 3 and 5-year after SBRT, respectively. Univariate analysis showed that favorable primary site (colorectal, breast and gynecological) of metastases (p = 0.001) improved survival. Toxicity was moderate. One patient experienced G3 late chest wall pain, which resolved within 1 year from SBRT. No cases of Radiation Induced Liver Disease (RILD) were detected. Conclusions: Long-term results of this Phase II study suggest the efficacy and safety of SBRT for un-resectable liver metastases after 5-year of follow up. Selection of cases with positive prognostic factors may improve long-term survival of these oligo-metastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.

引用

页数：10

共 43 条

[1] Is liver resection justified for patients with hepatic metastases from breast cancer? [J].